Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology SA has completed a private placement, issuing 6.5 million shares at USD 5.00 each, raising USD 32.5 million. The funds will support research and development, including clinical work on CAR T therapies CYAD-101 and CYAD-211, and advance other preclinical candidates. The shares sold are unregistered under U.S. securities laws and come with customary resale registration rights. Celyad focuses on CAR T therapies for cancer, with a growing pipeline of products.
Celyad Oncology has announced a private placement of 6,500,000 ordinary shares with Fortress Investment Group, generating gross proceeds of USD 32.5 million (approximately EUR 28.7 million). The shares will be priced at USD 5.00 each, reflecting an 18.5% premium to the 30-day volume weighted average price. Proceeds will support R&D, including CAR T candidates CYAD-101 and CYAD-211. Following the placement, Fortress will hold 28.8% of Celyad's shares. This financing is expected to fund activities into the first half of 2023.
Celyad Oncology SA (CYAD) has announced a subscription agreement with Fortress Investment Group for the private placement of 6.5 million ordinary shares, generating gross proceeds of USD 32.5 million. The shares will be offered at USD 5.00 each, an 18.5% premium over the 30-day volume weighted average price. The funds will support research and development, including clinical trials for CAR T candidates CYAD-101 and CYAD-211. Fortress will acquire 28.8% of Celyad's shares and gain certain rights, including board nominations and rights on new equity issuance.
Celyad Oncology (Euronext & Nasdaq: CYAD) presented preclinical data at the SITC Annual Meeting, highlighting advancements in their allogeneic CAR T therapy programs. Key findings include the improvement of NKG2D CAR T cells' anti-tumor activity through IL-18 armoring, and the development of a second-generation shRNA scaffold for enhanced CAR T candidates. Notably, the KEYNOTE-B79 Phase 1b trial, evaluating CYAD-101 in combination with KEYTRUDA, is set to initiate in Q4 2021, targeting patients with microsatellite stable metastatic colorectal cancer, addressing a significant unmet medical need.
Celyad Oncology (CYAD) announced key developments in its clinical trials and financials for Q3 2021. The Phase 1b KEYNOTE-B79 trial is set to evaluate CYAD-101 with KEYTRUDA in mCRC patients by year-end 2021. Enrollment in the IMMUNICY-1 trial for CYAD-211 continues, with updates to be presented at the upcoming ASH Annual Meeting. The company secured a €3.5 million grant and signed a patent agreement for targeting GPC3. As of September 30, 2021, Celyad had €6.1 million in cash, down from €12 million in Q2.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced the acceptance of two abstracts for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting, scheduled for December 11-14, 2021, in Atlanta, Georgia. The presentations will focus on:
- CYAD-211 for relapsed/refractory multiple myeloma (poster presentation)
- CYAD-02 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes (oral session)
Both abstracts will also be published in the November issue of the journal Blood.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced its virtual participation in the Jefferies London Healthcare Conference on November 18-19, 2021. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including allogeneic and autologous candidates for hematological malignancies and solid tumors. Founded in 2007 and based in Belgium and New York, Celyad has received funding from the Walloon Region to support its CAR T cell programs. Investors are advised to review potential risks in the forward-looking statements in the release.
Celyad Oncology announced a capital increase of 300,000 new shares to Lincoln Park Capital Fund, LLC, boosting its share capital to 55,964,224.33 EUR across 16,093,956 shares. The company is focused on developing CAR T cell therapies for cancer. This move is part of a strategic effort to enhance financial capacity, which may impact shareholders by adding liquidity but could also dilute existing shares. The adjustment in capital structure is disclosed per Belgian regulations.
Celyad Oncology SA announced that three abstracts related to its allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 10-14, 2021. The presentations include insights on the company’s multiplexing capabilities using short hairpin RNA technology, its first allogeneic CAR T candidate CYAD-203, and the Phase 1b KEYNOTE-B79 trial of CYAD-101 for metastatic colorectal cancer patients. These findings highlight Celyad's advancements in CAR T therapies.
Celyad Oncology SA (Brussels:CYAD) announced its participation in several conferences in September 2021, including the Wells Fargo Virtual Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird’s Virtual Global Healthcare Conference. CEO Filippo Petti will present at these events, highlighting the company's focus on developing CAR T cell therapies for cancer. Celyad is based in Belgium and has received funding from the Walloon Region to support its initiatives. Further details can be found on their website.